Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG
Open Access
- 1 August 1992
- Vol. 68 (8), 167-170
- https://doi.org/10.1136/hrt.68.8.167
Abstract
Objective—To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. Design—Patients were randomly allocated to receive either 1·5 × 106 IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay). Setting—Cardiology department in a general hospital. Patients—128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion. Results—Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18). Conclusion—Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.Keywords
This publication has 10 references indexed in Scilit:
- Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS studyThe Lancet, 1990
- Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarctionThe Lancet, 1990
- Antistreptokinase titres after intravenous streptokinaseThe Lancet, 1990
- Significance of antibodies to streptokinase in coronary thrombolytic therapy with streptokinase or APSACFibrinolysis, 1988
- Activation of the complement system by recombinant tissue plasminogen activatorJournal of the American College of Cardiology, 1987
- Consequences of Antibody Binding in Vitro on the Pharmacological Properties of Anisoylated Plasminogen Streptokinase Activator ComplexDrugs, 1987
- Clinical effects and kinetic properties of intravenous APSAC — anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarctionInternational Journal of Cardiology, 1986
- Assessment of Anti-Streptokinase Antibody Levels in Human Sera Using a Microradioimmunoassay ProcedureThrombosis and Haemostasis, 1984
- Dextran hypersensitivityImmunology Today, 1982
- THE MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN. I. INDUCTION AND EFFECTS*Journal of Clinical Investigation, 1959